Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.
Kinoxis Therapeutics has raised $9.5M in total funding. The most recent round was Series B. The last funding was announced in August 2024.
Kinoxis Therapeutics's investors include National Institutes of Health, University of Sydney, Uniseed, Stoic VC, Brisbane Angels.
Kinoxis Therapeutics is headquartered in Melbourne, Australia.
Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.
Kinoxis Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kinoxis Therapeutics — Funding & Investors." VCBacked, August 12, 2024, https://www.vcbacked.co/company/kinoxis-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Kinoxis Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/kinoxis-therapeutics
{{cite web |title=Kinoxis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kinoxis-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated